This Cannabis Stock Is Down 95% From its All-Time High: Why the Rout May Not Be Over

The recent massive selloff in cannabis companies like The Green Organic Dutchman (TSX:TGOD) have seen may not be over — here’s why.

With speculation around U.S. legalization growing, cannabis stocks have seen significant volatility of late. Indeed, this volatility is for good reason. A number of U.S. states have already legalized recreational cannabis. Accordingly, expectations of federal legalization seemed like a no-brainer with the “blue wave” we saw take hold in U.S. politics last year.

That said, it appears sentiment is starting to shift. Indeed, cannabis stocks have been roiled of late, as investors reprice this catalyst. Let’s discuss what this means for cannabis players like The Green Organic Dutchman (TSX:TGOD) right now.

An infrastructural loss

Like several other Canadian cannabis companies, TGOD was preparing for a growth spurt with U.S. legalization. Indeed, this company was positioning itself as a player with the potential to have export capacity to serve the United States. Its domestic production investments were substantial and were cheered by the market during previous bull markets.

However, domestic demand hasn’t really materialized to the extend TGOD expected. And with the U.S. export market increasingly looking out of reach, TGOD is yet another cannabis company to announce some significant writedowns.

The Green Organic Dutchman recently announced the sale of one of its Quebec facilities to Cannara Biotech. As a result of the deal, TGOD will receive US$27 million in proceeds.

However, the company’s total investment in this facility was US$229 million. Accordingly, the company will take a loss of more than US$200 million on this project. Indeed, the 185,000 kg of capacity this facility was supposed to provide has gone up in smoke, along with the US$200 million the company poured into this endeavour.

Indeed, such a drastic move is a sign of the times for the Canadian cannabis space. Companies are scrambling to cut costs. If that means taking massive losses, so be it.

Accordingly, investors looking at cannabis players like TGOD now may be wondering what they’re valuing. If these companies’ existing assets get revalued, things could turn ugly for these stocks. Indeed, one can make the argument some serious mismanagement of capital has taken place in this sector. How much gets written down before it’s all said and done is the big question many investors have right now.

Bottom line

The cannabis sector is a great example of a segment of the stock market that has seen valuations swing wildly. While some may argue that the selloffs we’ve seen have been as much of an overreaction as the parabolic spikes upward, this appears to be a true statement.

That said, the capital-allocation missteps of companies like TGOD stand as a reminder of what downside could be on the horizon for this sector. Indeed, over-exuberance for any asset class can turn out to be detrimental for long-term investors. In my view, this level of overexuberance still exists to some degree in the cannabis space today. Accordingly, further downside could be on the horizon for these stocks in the near to medium term.

Fool contributor Chris MacDonald has no position in any stocks mentioned in this article.

More on Cannabis Stocks

Medicinal research is conducted on cannabis.
Cannabis Stocks

Top Canadian Stocks to Buy Right Now With $1,000

Cannara, Source Energy and CareRx just updated investors. See what $1,000 can buy in these Canadian stocks, plus the risks…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

This Cannabis Stock Jumped 12% in a Day: The Math Says Be Careful

Tilray's record revenue came with declining cannabis sales and negative free cash flow, making the investment much more speculative than…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Curaleaf’s Takeover Bid for Aurora Cannabis: What Investors Need to Know

Curaleaf's takeover bid for Aurora Cannabis offers a premium but brings stock, debt, and deal risks. Here’s what ACB investors…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Curaleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here’s What This Means for Investors.

It's appealing directly to the Canadian company's shareholders with a cash-and-stock offer.

Read more »

runner checks her biodata on smartwatch
Cannabis Stocks

Average TFSA and RRSP Balances at Age 45: Are You on Par?

Most 45-year-olds have less than $100,000 combined in their TFSA and RRSP. Here's how TerrAscend could help you close the…

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Risky Stocks That Could Send Your $100,000 Investment to $0

Cannabis stocks look risky because price wars, dilution, and regulation can turn one weak quarter into a long drawdown.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

My Biggest Investing Regret in 2025 Was Buying This Stock

Canopy Growth is a cautionary reminder to buy businesses, not headlines, especially in hype-driven sectors like cannabis.

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Popular Stocks That Could Wipe Out a $100,000 Nest Egg

Aurora Cannabis (TSX:ACB) is one stock that could wipe out your nest egg.

Read more »